<h2>Oncolytic Virus Therapies Market Trends &amp; Forecast: USD 270.28 Million by 2023</h2>
<p>The global <a href="https://straitsresearch.com/report/oncolytic-virus-therapies-market">Oncolytic Virus Therapies Market</a> was valued at <strong>USD 214 million</strong> in <strong>2022</strong> and is projected to reach <strong>USD 270.28 million</strong> in <strong>2023</strong>, with an estimated value of <strong>USD 970 million</strong> by <strong>2031</strong>. The market is expected to grow at a <strong>CAGR of 26.3%</strong> during the forecast period (<strong>2023&ndash;2031</strong>), driven by growing investments in cancer therapies and advancements in viral-based treatment methods.</p>
<h3><strong>Oncolytic Virus Therapies Market Catalysts for Expansion</strong></h3>
<p>Oncolytic virus therapy has gained significant attention as a promising treatment option for cancer. The market is expanding due to the increasing prevalence of various cancers, including solid tumors and hematological malignancies, coupled with a rising demand for targeted therapies with fewer side effects. Furthermore, ongoing advancements in virotherapy research, including the development of genetically engineered oncolytic viruses, are significantly contributing to market growth. The increasing number of clinical trials, strategic partnerships, and government funding for research into oncolytic virus therapies are additional key drivers propelling the market forward.</p>
<h3><strong>Oncolytic Virus Therapies Market Segment Breakdown</strong></h3>
<p>The oncolytic virus therapies market is segmented into multiple categories, each driving the overall market growth in unique ways.</p>
<h4><strong>By Commercialized Therapies</strong></h4>
<ol>
<li><strong>Imlygic</strong></li>
<li><strong>Oncorine</strong></li>
<li><strong>RIGVIR</strong></li>
</ol>
<p>These commercially available therapies are integral to the expansion of the market, with Imlygic being one of the first FDA-approved oncolytic virus therapies for melanoma, setting the stage for other similar treatments.</p>
<h4><strong>By Pipeline Therapies</strong></h4>
<ol>
<li><strong>Phase I</strong></li>
<li><strong>Phase II</strong></li>
<li><strong>Phase III</strong></li>
<li><strong>Phase IV</strong></li>
</ol>
<p>Pipeline therapies are a significant area of growth, with many promising oncolytic virus candidates in various phases of clinical trials. The success of these therapies is expected to fuel the market as they move toward commercialization.</p>
<h4><strong>By Type of Virus</strong></h4>
<ul>
<li><strong>Genetically Engineered Oncolytic Virus</strong>
<ol>
<li><strong>Herpes Simplex Virus (HSV)</strong></li>
<li><strong>Adenovirus</strong></li>
<li><strong>Vaccinia Virus</strong></li>
<li><strong>Oncolytic Wild-Type Virus</strong></li>
</ol>
</li>
<li><strong>Reovirus (Respiratory Enteric Orphan Virus)</strong>
<ol>
<li><strong>Newcastle Disease Virus (NDV)</strong></li>
<li><strong>Vesicular Stomatitis Virus (VSV)</strong></li>
</ol>
</li>
</ul>
<p>Genetically engineered oncolytic viruses are playing an increasingly important role in targeting and killing cancer cells, with various types of viruses being explored for their effectiveness in different cancer types.</p>
<h4><strong>By Application</strong></h4>
<ol>
<li><strong>Solid Tumor</strong>
<ul>
<li><strong>Breast Cancer</strong></li>
<li><strong>Prostate Cancer</strong></li>
<li><strong>Lung Cancer</strong></li>
<li><strong>Glioblastoma</strong></li>
<li><strong>Melanoma</strong></li>
<li><strong>Other Applications</strong></li>
</ul>
</li>
<li><strong>Hematological Malignancies</strong>
<ul>
<li><strong>Lymphoma</strong></li>
<li><strong>Leukemia</strong></li>
<li><strong>Myeloma</strong></li>
</ul>
</li>
</ol>
<p><strong>Download Free Sample Report with&nbsp;Complimentary Analyst Consultation : <a href="https://straitsresearch.com/report/oncolytic-virus-therapies-market/request-sample">https://straitsresearch.com/report/oncolytic-virus-therapies-market/request-sample</a><br /></strong></p>
<p>The primary application of oncolytic virus therapy remains in treating solid tumors, with significant progress in cancers like melanoma, prostate, breast, and lung cancer. However, hematological malignancies, including lymphoma and leukemia, also represent a growing area of interest, with several promising trials underway.</p>
<h3><strong>Top Performing Companies in the Oncolytic Virus Therapies Market</strong></h3>
<p>Several leading pharmaceutical and biotech companies are spearheading the oncolytic virus therapies market. Some of the top-performing companies include:</p>
<ol>
<li><strong>Amgen Inc.</strong></li>
<li><strong>DAIICHI SANKYO COMPANY LIMITED</strong></li>
<li><strong>DNAtrix</strong></li>
<li><strong>Genelux</strong></li>
<li><strong>Oncolytics Biotech Inc.</strong></li>
<li><strong>PsiOxus Therapeutics</strong></li>
<li><strong>RIGVIR Ltd</strong></li>
<li><strong>Shanghai Sunway Biotech Co. Ltd.</strong></li>
<li><strong>SillaJen Inc.</strong></li>
<li><strong>Sorrento Therapeutics Inc.</strong></li>
<li><strong>Takara Bio Inc.</strong></li>
<li><strong>Transgene SA</strong></li>
<li><strong>VCNBiosciences</strong></li>
<li><strong>ViroCure</strong></li>
<li><strong>Viralytics Ltd. (Merck &amp; Co., Inc.)</strong></li>
</ol>
<p>These companies are actively involved in the development, commercialization, and clinical trial phases of oncolytic virus therapies. They are continuously innovating and expanding their product pipelines to meet the rising demand for more effective cancer treatments.</p>
<h3><strong>Emerging Prospects in the Oncolytic Virus Therapies Market</strong></h3>
<p>The oncolytic virus therapies market holds immense potential for growth in the coming years. One of the most promising developments is the combination of oncolytic virus therapy with other treatment modalities, such as immunotherapy and chemotherapy, which may enhance the therapeutic outcomes. The integration of these treatments has shown promising results in pre-clinical studies, and further clinical trials are expected to validate their efficacy. Additionally, the continuous development of engineered viruses with improved specificity and lower toxicity profiles is expected to expand the therapeutic applications of oncolytic virotherapy.</p>
<p>Another key prospect is the growing focus on personalized cancer therapies. Oncolytic viruses are being tailored to target specific types of cancer cells, making them a powerful tool for precision medicine. As these therapies advance, they are expected to provide better outcomes for patients and further increase their adoption worldwide.</p>
<h3><strong>Industry Movements and Trends</strong></h3>
<p>Key movements and trends in the oncolytic virus therapies industry include:</p>
<ul>
<li><strong>Increased Investment in Research and Development</strong>: Both public and private sectors are increasing their investment in R&amp;D activities for oncolytic viruses, which will drive the development of new therapies.</li>
<li><strong>Collaborations and Partnerships</strong>: Pharmaceutical companies are forming strategic partnerships with biotech firms to co-develop therapies and expand their product offerings.</li>
<li><strong>Regulatory Advancements</strong>: With several oncolytic virus therapies receiving breakthrough therapy designations and accelerated approval from regulatory bodies, the path to market for new therapies is becoming quicker and more efficient.</li>
<li><strong>Personalized Medicine</strong>: A growing trend toward personalized cancer treatment is fostering the use of oncolytic viruses as part of individualized treatment plans tailored to the patient&rsquo;s specific cancer profile.</li>
</ul>
<h3><strong>Geographic Analysis</strong></h3>
<p>The oncolytic virus therapies market is witnessing growth across various regions. North America holds a dominant position due to its advanced healthcare infrastructure, robust research and development activities, and high adoption rate of new cancer therapies. Europe is also a significant market, driven by increasing investments in cancer treatment and strong clinical trial activity. The Asia-Pacific region, especially China and Japan, is expected to see rapid growth in the coming years, as countries in this region focus on enhancing healthcare access and oncology care. Meanwhile, Latin America and the Middle East are emerging as potential markets with increasing healthcare investments and clinical trials.</p>
<h3><strong>Oncolytic Virus Therapies Market Data Insights</strong></h3>
<p>Straits Research&rsquo;s comprehensive market analysis provides valuable insights into the oncolytic virus therapies market. The report covers market size, trends, segment analysis, competitive landscape, and regional insights. This in-depth data empowers stakeholders in the pharmaceutical and biotech industries to make informed decisions and capitalize on emerging opportunities in the rapidly evolving oncolytic virus therapy space.</p>
<p>For more detailed insights and to request a customized report, please contact us.</p>
<p><strong>Contact Us</strong><br />Email: <a rel="">sales@straitsresearch.com</a><br />Phone: +1 646 905 0080 (US), +91 8087085354 (India), +44 203 695 0070 (UK)</p>
